Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

GTHPGUIDED THERAPEUTICS INC

OTC · CIK 0000924515
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC3845 Electromedical & Electrotherapeutic Apparatus
FY end1231
XBRL facts467

Identity from submissions API

NameGUIDED THERAPEUTICS INC
CIK0000924515
TickersGTHP
ExchangesOTC
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC3845 Electromedical & Electrotherapeutic Apparatus
EIN582029543
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone7702428723
Website—
Investor website—
Owner org08 Industrial Applications and Services
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • SPECTRX INC (1997-11-12T05:00:00.000Z → 2008-02-28T05:00:00.000Z)
Business address
5835 PEACHTREE CORNERS EAST
SUITE B
PEACHTREE CORNERS
GA
30092
GA
Mailing address
5835 PEACHTREE CORNERS EAST
SUITE B
PEACHTREE CORNERS
GA
30092
GA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1162 filing rows loaded from submissions recent; extra archives: CIK0000924515-submissions-001.json (162 filings, 1997-02-27 to 2004-04-21).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 10-Q FORM 10-Q 0001477932-26-007012 000-22179 261559161 34 8169584 1 1
2026-10-27 4 FORM 4 0001477932-26-006467 7759
2026-08-13 10-Q FORM 10-Q 0001477932-26-004958 000-22179 261271747 34 8445683 1 1
2026-05-15 10-Q FORM 10-Q 0001477932-26-003195 000-22179 26985200 34 6863655 1 1
2026-05-05 4 FORM 4 0001477932-26-002770 30262
2026-04-07 4 FORM 4 0001477932-26-002054 5707
2026-04-07 4 FORM 4 0001477932-26-002052 14858
2026-04-07 4 FORM 4 0001477932-26-002048 5720
2026-03-31 10-K FORM 10-K 0001477932-26-001723 000-22179 26815966 34 10285851 1 1
2026-03-12 4 FORM 4 0001477932-26-001320 33664
2026-03-10 8-K FORM 8-K 1.01,3.02,8.01,9.01 0001477932-26-001252 000-22179 26736614 34 136027 1 1
2026-03-04 4 FORM 4 0001477932-26-001162 15786
2025-11-13 10-Q FORM 10-Q 0001477932-25-008196 000-22179 251479457 34 9550311 1 1
2025-09-05 4 FORM 4 0001477932-25-006531 12321
2025-09-05 4 FORM 4 0001477932-25-006528 12194
2025-09-05 4 FORM 4 0001477932-25-006522 13820
2025-09-05 4 FORM 4 0001477932-25-006513 7370
2025-08-14 10-Q FORM 10-Q 0001477932-25-005887 000-22179 251217896 34 8427254 1 1
2025-06-13 4 FORM 4 0001477932-25-004576 5601
2025-06-12 4 FORM 4 0001477932-25-004560 5585
2025-06-12 4 FORM 4 0001477932-25-004559 5592
2025-05-23 4/A FORM 4 A 0001477932-25-004137 25162
2025-05-15 10-Q FORM 10-Q 0001477932-25-003835 000-22179 25954884 34 7836231 1 1
2025-04-17 4 FORM 4 0001477932-25-002818 24011
2025-04-08 4 FORM 4 0001477932-25-002516 11270
2025-03-31 10-K FORM 10-K 0001477932-25-002200 000-22179 25792000 34 9500375 1 1
2025-02-18 4 FORM 4 0001477932-25-001072 4843
2024-12-23 8-K FORM 8-K 1.01,9.01 0001477932-24-008254 000-22179 241569225 34 441256 1 1
2024-12-20 4 FORM 4 0001477932-24-008256 7265
2024-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001700205-24-000005 005-51261 241459513 34 81291
2024-11-14 10-Q FORM 10-Q 0001477932-24-007162 000-22179 241458790 34 8180394 1 1
2024-10-25 4 FORM 4 0001477932-24-006671 4843
2024-10-24 4 FORM 4 0001477932-24-006656 7641
2024-10-02 4 FORM 4 0001477932-24-006161 7266
2024-09-27 8-K FORM 8-K 1.01,9.01 0001477932-24-005960 000-22179 241329960 34 455718 1 1
2024-09-09 4 FORM 4 0001477932-24-005604 7981
2024-09-06 4 FORM 4 0001477932-24-005592 7990
2024-09-04 4 FORM 4 0001477932-24-005518 5635
2024-09-03 4 FORM 4 0001477932-24-005458 10235
2024-08-23 4 FORM 4 0001477932-24-005227 4838
2024-08-22 4 FORM 4 0001477932-24-005207 4846
2024-08-22 4 FORM 4 0001477932-24-005206 4869
2024-08-14 10-Q FORM 10-Q 0001477932-24-004869 000-22179 241209691 34 13936342 1 1
2024-08-01 4 FORM 4 0001477932-24-004509 4843
2024-05-14 10-Q FORM 10-Q 0001477932-24-002788 000-22179 24940728 34 5947378 1 1
2024-04-19 4 FORM 4 0001477932-24-002247 6499
2024-04-05 4 FORM 4 0001477932-24-001900 6526
2024-03-28 10-K FORM 10-K 0001477932-24-001549 000-22179 24800360 34 8333984 1 1
2024-03-22 4 FORM 4 0001477932-24-001435 7681
2024-02-22 4 FORM 4 0001477932-24-000856 6499
2024-02-20 SC 13G/A rosalind_gthp_13ga_19feb.htm 0001622627-24-000014 005-51261 24652191 34 89186
2024-02-14 SC 13G/A gthp_13gv2.htm 0001700205-24-000003 005-51261 24635700 34 110924
2023-12-08 4 FORM 4 0001477932-23-009031 13381
2023-11-13 10-Q FORM 10-Q 0001477932-23-008286 000-22179 231398155 34 7330982 1 1
2023-09-20 4 FORM 4 0001477932-23-006982 9561
2023-09-11 4 FORM 4 0001477932-23-006793 4734
2023-09-07 4 FORM 4 0001477932-23-006714 10791
2023-08-10 10-Q FORM 10-Q 0001477932-23-005869 000-22179 231158818 34 7257498 1 1
2023-06-27 4 FORM 4 0001477932-23-004807 17415
2023-06-27 4 FORM 4 0001477932-23-004806 5538
2023-06-27 4 FORM 4 0001477932-23-004805 5860
2023-06-27 4 FORM 4 0001477932-23-004804 9187
2023-06-26 4 FORM 4 0001477932-23-004759 4729
2023-06-26 4 FORM 4 0001477932-23-004758 5474
2023-06-26 4 FORM 4 0001477932-23-004757 9146
2023-06-20 3 FORM 3 0001477932-23-004665 9444
2023-06-02 4 FORM 4 0001477932-23-004226 5490
2023-06-02 4 FORM 4 0001477932-23-004225 9138
2023-05-15 10-Q FORM 10-Q 0001477932-23-003493 000-22179 23920545 34 6566247 1 1
2023-03-30 10-K FORM 10-K 0001477932-23-001899 000-22179 23776500 34 9268517 1 1
2023-03-09 8-K FORM 8-K 5.02 0001477932-23-001383 000-22179 23720152 34 141234 1 1
2023-02-14 SC 13G/A gthpv5.htm 0001700205-23-000002 005-51261 23625967 34 110861
2023-01-25 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2023-01-25 16:00:00 9999999995-23-000185 333-269229 23553807 33 1845
2023-01-23 CORRESP filename1.htm 0001477932-23-000494 7609
2023-01-23 UPLOAD filename1.pdf 0000000000-23-000693 40426
2023-01-13 S-1 FORM S-1 0001477932-23-000284 333-269229 23529408 33 15309774 1 1
2022-12-02 RW RW 0001477932-22-009056 333-259871 221442811 NE 6321
2022-11-14 10-Q FORM 10-Q 0001477932-22-008459 000-22179 221383418 34 7488893 1 1
2022-10-24 SC 13G gthpv3.hm.htm 0001700205-22-000003 005-51261 221326228 34 110905
2022-09-15 8-K FORM 8-K 1.01,3.02,8.01,9.01 0001477932-22-006945 000-22179 221246537 34 878444 1 1
2022-08-15 10-Q FORM 10-Q 0001477932-22-006064 000-22179 221164717 34 7570744 1 1
2022-07-29 8-K FORM 8-K 3.03,5.03,9.01 0001477932-22-005479 000-22179 221117119 34 149016 1 1
2022-07-13 S-1/A FORM S-1/A 0001477932-22-004988 333-259871 221080007 33 13936466 1 1
2022-07-06 SC 13G SC 13G 0001019056-22-000501 005-51261 221069206 34 133846
2022-06-30 S-1/A FORM S-1/A 0001477932-22-004756 333-259871 221056200 33 14579048 1 1
2022-05-16 10-Q FORM 10-Q 0001477932-22-003472 000-22179 22927619 34 6526674 1 1
2022-03-30 10-K FORM 10-K 0001477932-22-001704 000-22179 22782712 34 11191327 1 1
2022-02-17 S-1/A FORM S-1/A 0001654954-22-001803 333-259871 22649430 33 17095480 1 1
2022-01-07 8-K FORM 8-K 3.03,5.03,9.01 0001654954-22-000294 000-22179 22516383 34 153598 1 1
2021-11-15 10-Q FORM 10Q 0001654954-21-012222 000-22179 211410974 34 7668153 1 1
2021-10-07 S-1/A FORM S-1/A 0001568276-21-001658 333-259871 211310828 33 15767760 1 1
2021-09-29 S-1 FORM S-1 0001568276-21-001601 333-259871 211288856 33 15749018 1 1
2021-09-07 8-K PRIMARY DOCUMENT 1.01,8.01,9.01 0001654954-21-009799 000-22179 211238107 34 382624 1 1
2021-08-18 10-Q PRIMARY DOCUMENT 0001654954-21-009195 000-22179 211186421 34 8987579 1 1
2021-08-18 10-Q/A 10-Q/A 0001654954-21-009188 000-22179 211186276 34 4158822 1
2021-08-16 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-21-000024 000-22179 211179856 34 29394
2021-07-27 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-21-000023 000-22179 211118409 34 48374
2021-07-09 10-K/A GUIDED THERAPEUTICS, INC. 0001121781-21-000021 000-22179 211083468 34 182602
2021-07-07 8-K GUIDED THERAPEUTICS, INC. 8.01 0001121781-21-000019 000-22179 211077885 34 13798
2021-07-06 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-21-000017 000-22179 211072224 34 585533
2021-06-22 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-21-000015 000-22179 211032877 34 618564
2021-06-10 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,5.03,9.01 0001121781-21-000013 000-22179 211008693 34 136369
2021-05-21 10-Q PRIMARY DOCUMENT 0001654954-21-006101 000-22179 21945754 34 5048829 1
2021-05-17 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-21-000009 000-22179 21929562 34 28412
2021-04-07 10-K ANNUAL REPORT 0001654954-21-003915 000-22179 21810346 34 9052874 1
2021-03-31 NT 10-K GUIDED THERAPEUTICS, INC. 0001121781-21-000005 000-22179 21793455 34 26863
2020-11-05 10-Q/A GUIDED THERAPEUTICS, INC. 0001121781-20-000080 000-22179 201289267 34 5261549 1
2020-11-05 10-Q GUIDED THERAPEUTICS, INC. 0001121781-20-000075 000-22179 201289156 34 1142550
2020-10-15 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-10-15 16:00:00 9999999995-20-002856 333-248712 201242696 33 1846
2020-10-13 CORRESP filename1.htm 0001121781-20-000073 11930
2020-10-08 S-1/A S-1/A 0001654954-20-010924 333-248712 201229938 33 10398002 1
2020-09-16 8-K GUIDED THERAPEUTICS, INC. 5.02 0001121781-20-000067 000-22179 201177880 34 17496
2020-09-14 UPLOAD filename1.pdf 0000000000-20-008646 40457
2020-09-10 S-1 FORM S-1 0001654954-20-009997 333-248712 201169283 33 10248934 1
2020-08-20 10-Q QUARTERLY REPORT 0001654954-20-009366 000-22179 201117973 34 6398783 1
2020-08-17 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-20-000062 000-22179 201108210 34 28576
2020-07-07 10-Q QUARTERLY REPORT 0001654954-20-007405 000-22179 201015801 34 4656925 1
2020-06-29 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-20-000046 000-22179 20997345 34 28431
2020-05-18 8-K GUIDED THERAPEUTICS, INC. 8.01 0001121781-20-000041 000-22179 20888734 34 17545
2020-04-20 10-K ANNUAL REPORT 0001654954-20-004236 000-22179 20802309 34 13837839 1
2020-03-31 8-K GUIDED THERAPEUTICS, INC. 8.01 0001121781-20-000024 000-22179 20760312 34 17433
2020-03-09 10-Q GUIDED THERAPEUTICS, INC. 0001121781-20-000018 000-22179 20698004 34 4075831 1
2020-02-11 10-Q GUIDED THERAPEUTICS, INC. 0001121781-20-000011 000-22179 20594573 34 4031256 1
2019-08-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-19-000069 000-22179 191029932 34 28793
2019-07-11 10-Q GUIDED THERAPEUTICS, INC. 0001121781-19-000058 000-22179 19951481 34 3684529 1
2019-05-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-19-000036 000-22179 19827439 34 28473
2019-05-08 10-K FORM 10-K 0001654954-19-005469 000-22179 19807779 34 5547094 1
2019-04-03 8-K GUIDED THERAPEUTICS, INC. 5.02 0001121781-19-000020 000-22179 19728833 34 20984
2019-04-01 NT 10-K GUIDED THERAPEUTICS, INC. 0001121781-19-000018 000-22179 19719336 34 27264
2018-11-15 8-K GUIDED THERAPEUTICS, INC. 5.03,9.01 0001121781-18-000070 000-22179 181185354 34 37291
2018-11-14 10-Q GUIDED THERAPEUTICS, INC. 0001121781-18-000063 000-22179 181181703 34 2945639 1
2018-10-25 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-18-000056 000-22179 181137854 34 40582
2018-10-11 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-18-000046 000-22179 181117444 34 489550
2018-09-28 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-18-000042 000-22179 181093009 34 470548
2018-09-17 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-18-000035 000-22179 181073364 34 455867
2018-09-06 8-K CURRENT REPORT 1.01,3.02,5.03,9.01 0001654954-18-009920 000-22179 181057227 34 180511
2018-09-05 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-18-000033 000-22179 181054393 34 455642
2018-08-14 10-Q QUARTERLY REPORT 0001654954-18-009034 000-22179 181015361 34 3058150 1
2018-07-10 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2018-07-10 16:00:00 9999999995-18-001746 333-225613 18947962 33 1827
2018-07-09 CORRESP filename1.htm 0001121781-18-000028 6806
2018-07-02 UPLOAD filename1.pdf 0000000000-18-020357 38786
2018-06-14 S-1 REGISTRATION STATEMENT 0001654954-18-006646 333-225613 18898691 33 6108693 1
2018-05-25 SC 13D SC 13D 0001193125-18-174721 005-51261 18860537 34 32758
2018-05-25 3 FORM 3 SUBMISSION 0000899243-18-014024 8210
2018-05-21 10-Q GUIDED THERAPEUTICS, INC. 0001121781-18-000024 000-22179 18848766 34 2692253 1
2018-05-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-18-000019 000-22179 18833967 34 26527
2018-04-20 10-K/A PRIMARY DOCUMENT 0001654954-18-004170 000-22179 18765866 34 3970941 1
2018-04-17 10-K ANNUAL REPORT 0001654954-18-004021 000-22179 18758657 34 3963277 1
2018-04-02 NT 10-K GUIDED THERAPEUTICS, INC. 0001121781-18-000010 000-22179 18727721 34 26328
2017-11-20 10-Q GUIDED THERAPEUTICS, INC. 0001121781-17-000077 000-22179 171214809 34 2527839 1
2017-11-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-17-000076 000-22179 171204422 34 18329
2017-11-13 8-K/A GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-17-000071 000-22179 171192530 34 190082
2017-10-25 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-17-000059 000-22179 171153137 34 177571
2017-09-25 RW GUIDED THERAPEUTICS, INC. 0001121781-17-000056 333-212384 171099514 NE 5650
2017-08-24 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-17-000051 000-22179 171049832 34 187635
2017-08-18 10-Q QUARTERLY REPORT 0001654954-17-007742 000-22179 171040517 34 2739960 1
2017-08-17 8-K/A FORM 8K/A 1.01,9.01 0001654954-17-007712 000-22179 171038424 34 97341
2017-08-15 NT 10-Q NT 10-Q 0001654954-17-007608 000-22179 171033134 34 29174
2017-08-14 8-K CURRENT REPORT 1.01,9.01 0001654954-17-007533 000-22179 171030013 34 93883
2017-06-26 S-1/A PRIMARY DOCUMENT 0001654954-17-005874 333-212384 17930075 33 6326195 1
2017-06-07 S-1/A FORM S-1/A AMENDMENT NO. 4 0001654954-17-005425 333-212384 17897313 33 6903365 1
2017-05-24 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-17-000036 000-22179 17864826 34 1196928
2017-05-22 10-Q GUIDED THERAPEUTICS, INC. 0001121781-17-000030 000-22179 17859192 34 2496861 1
2017-05-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-17-000027 000-22179 17843795 34 17735
2017-03-31 S-1/A S-1/A 0001654954-17-002848 333-212384 17728480 33 4757153 1
2017-03-30 424B3 GUIDEN THERAPEUTICS, INC. 0001121781-17-000019 333-210387 17726602 33 26722
2017-03-30 8-K GUIDEN THERAPEUTICS, INC. 1.01 0001121781-17-000018 000-22179 17726550 34 37739
2017-03-24 424B3 PROSPECTUS SUPPLEMENT NO. 15 0001654954-17-002459 333-210387 17713662 33 119725
2017-03-24 8-K/A CURRENT REPORT AMENDMENT NO. 1 1.01,3.02,5.05,9.01 0001654954-17-002454 000-22179 17713288 34 113776
2017-03-22 10-K ANNUAL REPORT 0001654954-17-002258 000-22179 17706338 34 4040560 1
2017-03-09 SC 13G formsc13g.htm 0001493152-17-002284 005-51261 17677943 34 90580
2017-02-17 424B3 GUIDED THERAPEUTICS, INC. 0001121781-17-000013 333-210387 17619474 33 34149
2017-02-17 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-17-000012 000-22179 17619473 34 384579
2017-01-26 424B3 GUIDED THERAPEUTICS, INC. 0001121781-17-000008 333-210387 17548656 33 31900
2017-01-26 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,5.05,9.01 0001121781-17-000006 000-22179 17548645 34 178917
2017-01-12 S-1/A GUIDED THERAPEUTICS, INC. 0001121781-17-000004 333-212384 17525480 33 5459858 1
2016-12-30 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000605 333-210387 162077754 33 33622
2016-12-30 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-16-000604 000-22179 162077736 34 370596
2016-12-09 S-1/A GUIDED THERAPEUTICS, INC. 0001121781-16-000599 333-212384 162042665 33 5693719 1
2016-12-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000594 333-210387 162041574 33 22302
2016-12-08 8-K GUIDED THERAPEUTICS, INC. 5.02 0001121781-16-000593 000-22179 162041512 34 17987
2016-12-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000592 333-210387 162040017 33 27094
2016-12-07 8-K GUIDED THERAPEUTICS, INC. 1.01,9.01 0001121781-16-000591 000-22179 162039970 34 221673
2016-12-05 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000586 333-210387 162034563 33 372178
2016-12-05 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000585 000-22179 162034540 34 2436863 1
2016-11-18 3 OWNERSHIP DOCUMENT 0001121781-16-000576 11268
2016-11-17 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000574 333-210387 162005028 33 23200
2016-11-17 8-K GUIDED THERAPEUTICS, INC. 5.02 0001121781-16-000573 000-22179 162005004 34 18927
2016-11-15 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000569 000-22179 161999847 34 17733
2016-11-04 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000559 333-210387 161975398 33 27554
2016-11-04 8-K GUIDED THERAPEUTICS, INC. 1.01,8.01,9.01 0001121781-16-000558 000-22179 161975334 34 57608
2016-09-23 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000545 333-210387 161899594 33 40966
2016-09-23 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-16-000544 000-22179 161899573 34 37676
2016-09-09 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000540 333-210387 161877988 33 27460
2016-09-09 8-K/A GUIDED THERAPEUTICS, INC. 1.01,2.03,9.01 0001121781-16-000539 000-22179 161877971 34 36897
2016-09-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000537 333-210387 161876451 33 26606
2016-09-08 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,9.01 0001121781-16-000536 000-22179 161876426 34 36012
2016-08-26 DEFA14A GUIDED THERAPEUTICS, INC. 0001121781-16-000530 000-22179 161854145 34 23499
2016-08-25 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-16-000528 000-22179 161850973 34 163898
2016-08-19 UPLOAD filename1.pdf 0000000000-16-089297 36081
2016-08-18 PRER14A GUIDED THERAPEUTICS, INC. 0001121781-16-000520 000-22179 161840442 34 165473
2016-08-18 CORRESP filename1.htm 0001121781-16-000519 5743
2016-08-18 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-16-000517 000-22179 161840239 34 86780
2016-08-17 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000515 000-22179 161838711 34 2359363 1
2016-08-16 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000513 000-22179 161835136 34 17461
2016-08-12 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-16-000509 000-22179 161827930 34 164696
2016-08-12 CORRESP filename1.htm 0001121781-16-000508 27554
2016-08-03 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-16-000506 000-22179 161804670 34 165439
2016-08-03 CORRESP filename1.htm 0001121781-16-000505 25983
2016-07-27 UPLOAD filename1.pdf 0000000000-16-085965 160538
2016-07-19 CORRESP filename1.htm 0001654954-16-000863 25888
2016-07-19 PRER14A PRELIMINARY PROXY STATEMENT 0001654954-16-000862 000-22179 161773906 34 256395
2016-07-19 UPLOAD filename1.pdf 0000000000-16-084876 160975
2016-07-07 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-16-000501 000-22179 161756590 34 150950
2016-07-07 CORRESP filename1.htm 0001121781-16-000500 73524
2016-07-01 S-1 GUIDED THERAPEUTICS, INC. 0001121781-16-000497 333-212384 161747020 33 5302893 1
2016-06-29 UPLOAD filename1.pdf 0000000000-16-082605 160083
2016-06-15 CORRESP filename1.htm 0001121781-16-000491 6393
2016-06-15 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-16-000490 000-22179 161715355 34 150188
2016-06-14 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000488 333-210387 161712087 33 28296
2016-06-14 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-16-000486 000-22179 161712055 34 189517
2016-06-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000482 333-210387 161703702 33 30057
2016-06-08 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-16-000480 000-22179 161703674 34 107322 1
2016-05-19 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-16-000474 000-22179 161662103 34 68258 1
2016-05-19 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000472 000-22179 161662092 34 2386820 1
2016-05-17 NT 10-Q GUIDED THERAPEUTICS, INC. 0001121781-16-000468 000-22179 161656200 34 17184
2016-05-11 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000459 333-210387 161640805 33 20712
2016-05-11 8-K GUIDED THERAPEUTICS, INC. 5.02 0001121781-16-000458 000-22179 161640746 34 16258
2016-05-04 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000454 333-210387 161616740 33 34875
2016-05-03 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,5.03,9.01 0001121781-16-000452 000-22179 161616604 34 157180
2016-04-18 SC 13G SCHEDULE 13G 0001078782-16-002658 005-51261 161576429 34 49625
2016-04-07 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2016-04-07 17:00:00 9999999995-16-004165 333-210387 161561226 33 1828
2016-04-07 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000436 333-210387 161560844 33 801750
2016-04-05 CORRESP filename1.htm 0001121781-16-000434 17423
2016-03-31 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-16-000429 000-22179 161543762 34 53491 1
2016-03-24 S-1 GUIDED THERAPEUTICS, INC. 0001121781-16-000424 333-210387 161527093 33 3540195 1
2016-03-15 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-16-000422 000-22179 161507048 34 151417 1
2016-03-15 10-K GUIDED THERAPEUTICS, INC. 0001121781-16-000420 000-22179 161506800 34 3559759 1
2016-03-07 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000416 333-207201 161489236 33 25834
2016-03-07 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000415 333-205676 161489224 33 25720
2016-03-07 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000414 333-203589 161489217 33 25707
2016-03-07 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000413 333-198733 161489210 33 26071
2016-03-07 8-K GUIDED THERAPEUTICS, INC. 1.01,9.01 0001121781-16-000411 000-22179 161488465 34 46776
2016-02-23 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000405 333-207201 161449281 33 27314
2016-02-23 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000404 333-205676 161449269 33 27215
2016-02-23 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000403 333-203589 161449251 33 27400
2016-02-23 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000402 333-198733 161449236 33 27993
2016-02-23 8-K GUIDED THERAPEUTICS, INC. 8.01,9.01 0001121781-16-000400 000-22179 161448231 34 42230
2016-02-16 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000394 333-207201 161421644 33 47647
2016-02-16 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000393 333-205676 161421638 33 47665
2016-02-16 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000392 333-203589 161421629 33 47915
2016-02-16 424B3 GUIDED THERAPEUTICS, INC. 0001121781-16-000391 333-198733 161421619 33 48086
2016-02-16 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,2.04,3.02,5.02,9.01 0001121781-16-000390 000-22179 161421423 34 671348
2015-12-18 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000354 333-207201 151294715 33 20066
2015-12-18 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000353 333-205676 151294709 33 20063
2015-12-18 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000352 333-203589 151294707 33 20057
2015-12-18 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000351 333-198733 151294706 33 20190
2015-12-17 10-Q/A GUIDED THERAPEUTICS, INC. 0001121781-15-000350 000-22179 151294581 34 24264
2015-11-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000325 333-207201 151230097 33 321597
2015-11-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000324 333-205676 151230087 33 321492
2015-11-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000323 333-203589 151230078 33 321595
2015-11-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000322 333-198733 151230055 33 321526
2015-11-13 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-15-000320 000-22179 151228946 34 120616
2015-11-12 10-Q GUIDED THERAPEUTICS, INC. 0001121781-15-000315 000-22179 151225065 34 2072368 1
2015-11-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000312 333-207201 151223894 33 48737
2015-11-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000311 333-205676 151223884 33 48761
2015-11-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000310 333-203589 151223879 33 48654
2015-11-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000309 333-198733 151223870 33 48946
2015-11-12 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-15-000307 000-22179 151223151 34 45408
2015-11-10 8-K GUIDED THERAPEUTICS, INC. 8.01,9.01 0001121781-15-000303 000-22179 151218330 34 44011
2015-10-16 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2015-10-16 17:00:00 9999999995-15-002776 333-207201 151162935 33 1828
2015-10-16 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000293 333-207201 151162667 33 1016117
2015-10-15 UPLOAD filename1.pdf 0000000000-15-049910 188969
2015-10-15 CORRESP filename1.htm 0001121781-15-000291 9093
2015-10-14 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000287 000-22179 151158224 34 134629
2015-10-07 SC 13G/A dbm13ga.txt 0001310611-15-000004 005-51261 151148559 34 10358
2015-10-05 SC 13G dbm13gq315.txt 0001310611-15-000003 005-51261 151141633 34 10864
2015-10-02 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000279 000-22179 151140987 34 134598
2015-09-30 S-1 GUIDED THERAPEUTICS, INC. 0001121781-15-000275 333-207201 151133573 33 4572581 1
2015-09-15 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000263 333-203589 151107711 33 31734
2015-09-15 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000262 333-205676 151107702 33 31769
2015-09-15 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000260 333-198733 151107695 33 32191
2015-09-15 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-15-000258 000-22179 151107323 34 27529
2015-09-03 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000252 333-205676 151091910 33 32472
2015-09-03 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000250 333-203589 151091894 33 32582
2015-09-03 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000248 333-198733 151091886 33 32673
2015-09-03 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,3.03,5.03,9.01 0001121781-15-000246 000-22179 151091758 34 106173
2015-08-20 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-15-000244 000-22179 151065880 34 45048
2015-08-20 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-15-000242 000-22179 151065732 34 43298
2015-08-13 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-15-000232 000-22179 151050953 34 126606
2015-08-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000230 333-203589 151049030 33 354112
2015-08-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000228 333-205676 151049000 33 354423
2015-08-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000226 333-198733 151048991 33 354574
2015-08-13 10-Q GUIDED THERAPEUTICS, INC. 0001121781-15-000224 000-22179 151048792 34 2131423 1
2015-07-31 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000215 000-22179 151019299 34 125046
2015-07-30 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2015-07-30 17:00:00 9999999995-15-002118 333-205676 151017752 33 1828
2015-07-30 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000213 333-205676 151017204 33 884854
2015-07-29 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-15-000211 000-22179 151010563 34 42502
2015-07-28 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000209 333-205676 151008417 33 884224
2015-07-28 CORRESP filename1.htm 0001121781-15-000207 6790
2015-07-24 UPLOAD filename1.pdf 0000000000-15-038435 153865
2015-07-20 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000205 000-22179 15995296 34 125042
2015-07-17 4 OWNERSHIP DOCUMENT 0001121781-15-000201 9157
2015-07-17 4 OWNERSHIP DOCUMENT 0001121781-15-000199 15796
2015-07-17 4 OWNERSHIP DOCUMENT 0001121781-15-000197 23827
2015-07-15 D xslFormDX01/primary_doc.xml 06b 0000924515-15-000001 021-243795 15989144 33 12510
2015-07-15 S-1 GUIDED THERAPEUTICS, INC. 0001121781-15-000195 333-205676 15989057 33 4089731 1
2015-07-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000193 333-203589 15985833 33 25298
2015-07-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000191 333-198733 15985817 33 25354
2015-07-13 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-15-000189 000-22179 15985784 34 59513
2015-06-30 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000179 333-203589 15960797 33 49559
2015-06-30 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000177 333-198733 15960791 33 50004
2015-06-30 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-15-000175 000-22179 15960036 34 1040832
2015-06-19 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000166 333-203589 15941852 33 26941
2015-06-19 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000165 333-198733 15941850 33 27273
2015-06-19 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,5.03,9.01 0001121781-15-000164 000-22179 15941848 34 27880
2015-06-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000159 333-203589 15916936 33 57553
2015-06-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000157 333-198733 15916919 33 57655
2015-06-05 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-15-000155 000-22179 15916806 34 63834
2015-05-29 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-15-000150 000-22179 15898418 34 32396
2015-05-20 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-15-000146 000-22179 15879736 34 51543
2015-05-18 SC 13G MUSKET 13G 0001310611-15-000002 005-51261 15872884 34 10563
2015-05-14 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-15-000128 000-22179 15863266 34 104717
2015-05-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000124 333-203589 15859191 33 256158
2015-05-13 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000123 333-198733 15859177 33 256372
2015-05-13 10-Q GUIDED THERAPEUTICS, INC. 0001121781-15-000121 000-22179 15858384 34 2339920 1
2015-05-07 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2015-05-07 17:00:00 9999999995-15-001265 333-203589 15843851 33 1827
2015-05-07 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001121781-15-000087,2015-05-07 9999999995-15-001254 333-198733 15843844 33 1840
2015-05-07 424B4 GUIDED THERAPEUTICS, INC. 0001121781-15-000115 333-203589 15842876 33 927327
2015-05-07 424B4 GUIDED THERAPEUTICS, INC. 0001121781-15-000114 333-198733 15842861 33 667585
2015-05-07 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-15-000111 000-22179 15841718 34 75088
2015-04-27 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000089 000-22179 15794552 34 170829
2015-04-23 POS AM GUIDED THERAPEUTICS, INC. 0001121781-15-000087 333-198733 15789066 33 4035327 1
2015-04-23 S-1 GUIDED THERAPEUTICS, INC. 0001121781-15-000085 333-203589 15788995 33 4323137 1
2015-04-16 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-15-000075 000-22179 15774274 34 37061
2015-04-14 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-15-000073 000-22179 15769303 34 171078
2015-04-10 4 OWNERSHIP DOCUMENT 0001121781-15-000070 4717
2015-04-10 4 OWNERSHIP DOCUMENT 0001121781-15-000068 4711
2015-03-30 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-15-000058 000-22179 15734560 34 112811
2015-03-25 10-K GUIDED THERAPEUTICS, INC. 0001121781-15-000054 000-22179 15724820 34 3965016 1
2015-03-19 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000052 333-198733 15713048 33 26622
2015-03-19 424B3 GUIDED THERAPEUTICS, INC. 0001121781-15-000051 333-195603 15713032 33 25896
2015-03-19 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-15-000049 000-22179 15712974 34 76845
2015-01-16 4 OWNERSHIP DOCUMENT 0001121781-15-000006 4717
2015-01-16 4 OWNERSHIP DOCUMENT 0001121781-15-000004 4719
2014-12-19 UPLOAD filename1.pdf 0000000000-14-066045 34194
2014-12-19 CORRESP filename1.htm 0001121781-14-000383 9350
2014-12-17 UPLOAD filename1.pdf 0000000000-14-065068 157074
2014-12-09 4 OWNERSHIP DOCUMENT 0001121781-14-000374 6944
2014-12-09 4 OWNERSHIP DOCUMENT 0001121781-14-000372 6981
2014-12-04 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000368 333-195603 141264676 33 29479
2014-12-04 8-K/A GUIDED THERAPEUTICS, INC. 1.01,3.02,8.01,9.01 0001121781-14-000366 000-22179 141264644 34 492376
2014-12-03 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,8.01,9.01 0001121781-14-000364 000-22179 141263957 34 411138
2014-11-26 424B4 GUIDED THERAPEUTICS, INC. 0001121781-14-000359 333-198733 141253195 33 883249
2014-11-20 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000355 000-22179 141237834 34 39300
2014-11-19 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2014-11-19 16:00:00 9999999995-14-003456 333-198733 141237364 33 1828
2014-11-19 S-1/A GUIDED THERAPEUTICS, INC. 0001121781-14-000345 333-198733 141233570 33 5264104 1
2014-11-14 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-14-000334 000-22179 141223458 34 110225
2014-11-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000324 333-195603 141213393 33 261754
2014-11-12 10-Q GUIDED THERAPEUTICS, INC. 0001121781-14-000322 000-22179 141212890 34 2039456 1
2014-11-10 S-1/A GUIDED THERAPEUTICS, INC. 0001121781-14-000318 333-198733 141209789 33 1177726
2014-10-21 4 OWNERSHIP DOCUMENT 0001121781-14-000312 4719
2014-10-21 4 OWNERSHIP DOCUMENT 0001121781-14-000310 4637
2014-09-15 S-1 GUIDED THERAPEUTICS, INC. 0001121781-14-000293 333-198733 141101735 33 5276882 1
2014-09-10 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000290 333-195603 141096096 33 24420
2014-09-10 8-K GUIDED THERAPEUTICS, INC. 1.01,9.01 0001121781-14-000289 000-22179 141096086 34 169792
2014-09-08 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000285 333-195603 141091492 33 25571
2014-09-08 8-K GUIDED THERAPEUTICS, INC. 1.01,3.02,9.01 0001121781-14-000284 000-22179 141091473 34 164362
2014-08-20 4 OWNERSHIP DOCUMENT 0001121781-14-000273 4677
2014-08-20 4 OWNERSHIP DOCUMENT 0001121781-14-000271 4682
2014-08-20 4 OWNERSHIP DOCUMENT 0001121781-14-000269 4638
2014-08-20 4 OWNERSHIP DOCUMENT 0001121781-14-000267 4640
2014-08-18 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000251 333-195603 141049036 33 259038
2014-08-14 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-14-000244 000-22179 141043699 34 131903
2014-08-13 10-Q GUIDED THERAPEUTICS, INC. 0001121781-14-000235 000-22179 141037915 34 2093076 1
2014-07-28 8-K GUIDED THERAPEUTICS, INC. 9.01 0001121781-14-000223 000-22179 14996410 34 38628
2014-07-17 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000219 000-22179 14979764 34 37921
2014-07-08 4 OWNERSHIP DOCUMENT 0001121781-14-000217 9327
2014-07-08 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000215 000-22179 14964875 34 37854
2014-06-26 4 OWNERSHIP DOCUMENT 0001121781-14-000205 4610
2014-06-26 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000203 333-195603 14941715 33 46310
2014-06-20 8-K GUIDED THERAPEUTICS, INC. 5.07 0001121781-14-000201 000-22179 14933492 34 41897
2014-06-20 4 OWNERSHIP DOCUMENT 0001121781-14-000199 8539
2014-06-18 4 OWNERSHIP DOCUMENT 0001121781-14-000193 4539
2014-06-03 4 OWNERSHIP DOCUMENT 0001121781-14-000179 4766
2014-06-02 4 OWNERSHIP DOCUMENT 0001121781-14-000173 4764
2014-05-28 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000166 000-22179 14870810 34 76488
2014-05-23 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000164 000-22179 14867499 34 33309
2014-05-19 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000150 333-195603 14854061 33 222204
2014-05-19 8-K GUIDED THERAPEUTICS, INC. 2.02,7.01,9.01 0001121781-14-000148 000-22179 14854051 34 86919
2014-05-15 10-Q GUIDED THERAPEUTICS, INC. 0001121781-14-000134 000-22179 14847835 34 1857586 1
2014-05-13 DEF 14A GUIDED THERAPEUTICS, INC. 0001121781-14-000120 000-22179 14838046 34 153448
2014-05-13 D xslFormDX01/primary_doc.xml 06b 0000924515-14-000001 021-217241 14835977 33 12187
2014-05-12 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2014-05-12 17:00:00 9999999995-14-001435 333-195603 14835262 33 1827
2014-05-12 424B3 GUIDED THERAPEUTICS, INC. 0001121781-14-000118 333-195603 14834515 33 799420
2014-05-09 S-1/A GUIDED THERAPEUTICS, INC. 0001121781-14-000114 333-195603 14829349 33 3962589 1
2014-05-02 PRE 14A GUIDED THERAPEUTICS, INC. 0001121781-14-000110 000-22179 14809768 34 152675
2014-04-30 S-1 GUIDED THERAPEUTICS, INC. 0001121781-14-000108 333-195603 14800429 33 3970459 1
2014-04-24 8-K GUIDED THERAPEUTICS, INC. 1.01,2.03,3.02,9.01 0001121781-14-000096 000-22179 14780227 34 426279
2014-04-15 8-K GUIDED THERAPEUTICS, INC. 7.01,9.01 0001121781-14-000087 000-22179 14764425 34 37780

Latest XBRL company facts

One latest value per concept from companyfacts (467 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 98.19M 2026-11-11 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
dei EntityPublicFloat Entity Public Float USD 10.52M 2025-06-30 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap AccountsAndNotesReceivableNet Accounts and Financing Receivable, after Allowance for Credit Loss USD 2,000 2025-09-30 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.36M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AccountsPayableRelatedPartiesCurrent Accounts Payable, Related Parties, Current USD 29,000 2023-03-31 2023 Q1 10-Q 2023-05-15 0001477932-23-003493
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 2,669 2024-12-31 2024 FY 10-K 2025-03-31 0001477932-25-002200
us-gaap AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss USD 29,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 3,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AccretionExpense Accretion Expense USD 83,366 2023-07-01 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap AccruedBonusesCurrentAndNoncurrent Accrued Bonuses USD 570,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap AccruedLiabilities Accrued Liabilities (Deprecated 2009-01-31) USD 773,000 2011-06-30 2011 Q2 10-Q 2011-11-14 0001121781-11-000340
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.37M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AccruedLiabilitiesCurrentAndNoncurrent Accrued Liabilities USD 1.13M 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 40,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AccruedProfessionalFeesCurrentAndNoncurrent Accrued Professional Fees USD 37,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap AccruedRentCurrent Accrued Rent, Current USD 0 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 42,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AccruedVacationCurrentAndNoncurrent Accrued Vacation USD 40,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 1.58M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AdditionalLiabilityLongDurationInsuranceRemeasurementGainLoss AdditionalLiabilityLongDurationInsuranceRemeasurementGainLoss USD 62,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 149.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AdditionsToNoncurrentAssets Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2013-01-31) USD -107,000 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-26 0001121781-14-000055
us-gaap AdjustmentForAmortization Amortization USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities USD 682,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD 6,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001477932-24-004869
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 151,000 2021-01-01 2021-03-31 2021 Q1 10-Q/A 2021-08-18 0001654954-21-009188
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions APIC, Share-based Payment Arrangement, Recognition and Exercise USD 68,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 101,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 227,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 18,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 377,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 4,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) USD 19,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-15 0001121781-16-000420
us-gaap AllowanceForLoanAndLeaseLossRecoveryOfBadDebts Allowance for Loan and Lease Loss, Recovery of Bad Debts USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 0 2011-01-01 2011-12-31 2011 FY 10-K 2012-03-28 0001121781-12-000081
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 140,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 543,000 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001121781-15-000224
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 28,244 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap Assets Assets USD 1.38M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AssetsCurrent Assets, Current USD 734,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AssetsNet Net Assets USD -8.00M 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap AssetsNoncurrent Assets, Noncurrent USD 642,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment USD 18,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap BusinessAcquisitionProFormaEarningsPerShareBasic Business Acquisition, Pro Forma Earnings Per Share, Basic USD/shares -0.01 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap CapitalizedComputerSoftwareAdditions Capitalized Computer Software, Additions USD 640,000 1998-01-01 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap CapitalizedComputerSoftwareNet Capitalized Computer Software, Net USD 0 2011-12-31 2011 FY 10-K 2012-03-28 0001121781-12-000081
us-gaap CapitalUnitsAuthorized Capital Units, Authorized shares 145.00M 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap CapitalUnitsOutstanding Capital Units, Outstanding shares 62.19M 2012-09-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap Cash Cash USD 899,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 731,000 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 359,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 111,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 48,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -273,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap CashFDICInsuredAmount Cash, FDIC Insured Amount USD 2.06M 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0.4 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right shares 7.18M 2020-01-16 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 35.94M 2020-01-16 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 39.79M 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap CommitmentsAndContingencies Commitments and Contingencies USD 0 2019-12-31 2019 Q3 10-Q 2020-03-09 0001121781-20-000018
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 2.50M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockDividendsShares Common Stock Dividends, Shares shares 3.45M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap CommonStockOtherSharesOutstanding Common Stock, Other Shares, Outstanding shares 6.57M 2012-09-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 98,188 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 98,188 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockSharesSubscriptions Common Stock, Value, Subscriptions USD 351,000 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap CommonStocksIncludingAdditionalPaidInCapital Common Stocks, Including Additional Paid in Capital USD 103,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonStockValue Common Stock, Value, Issued USD 3.48M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CommonUnitOutstanding Common Unit, Outstanding shares 52.04M 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap ContractWithCustomerAssetReclassifiedToReceivable Contract with Customer, Asset, Reclassified to Receivable USD 120,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ContractWithCustomerReceivableAllowanceForCreditLoss Contract with Customer, Receivable, Allowance for Credit Loss USD 586 2024-12-31 2024 FY 10-K 2025-03-31 0001477932-25-002200
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 319,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 75,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted shares 414,082 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued shares 100,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap ConvertibleDebt Convertible Debt USD 2.40M 2019-12-17 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ConvertibleDebtCurrent Convertible Debt, Current USD 73,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap ConvertibleDebtFairValueDisclosures Convertible Debt, Fair Value Disclosures USD 388,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ConvertibleDebtNoncurrent Convertible Debt, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 1.11M 2024-03-31 2024 Q1 10-Q 2024-05-14 0001477932-24-002788
us-gaap ConvertibleNotesPayable Convertible Notes Payable USD 0 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 311,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value USD 105,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap CostOfGoodsSold Cost of Goods Sold (Deprecated 2018-01-31) USD 3,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-21 0001121781-18-000024
us-gaap CostOfRevenue Cost of Revenue USD 42,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap CostsAndExpenses Costs and Expenses USD 1.71M 2012-01-01 2012-03-31 2012 Q1 10-Q 2012-05-14 0001121781-12-000160
us-gaap CumulativeEarningsDeficit Cumulative Earnings (Deficit) USD -158.00M 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 33,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued shares 2.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DebtDefaultShorttermDebtAmount Debt Default, Short-term Debt, Amount USD 1.13M 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 217,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DebtInstrumentDecreaseForgiveness Debt Instrument, Decrease, Forgiveness USD 191,051 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 2.50M 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap DebtInstrumentFairValue Debt Instrument, Fair Value Disclosure USD 2.74M 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap DebtInstrumentIncreaseAccruedInterest Debt Instrument, Increase, Accrued Interest USD 116,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DebtInstrumentInterestRateDuringPeriod Debt Instrument, Interest Rate During Period pure 0.06 2024-04-01 2024-04-15 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage pure 0.046 2015-09-30 2015 Q3 10-Q 2015-11-12 0001121781-15-000315
us-gaap DebtInstrumentInterestRateEffectivePercentageRateRangeMaximum Debt Instrument, Interest Rate, Effective Percentage Rate Range, Maximum (Deprecated 2016-01-31) pure 0.18 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap DebtInstrumentInterestRateEffectivePercentageRateRangeMinimum Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum (Deprecated 2016-01-31) pure 0.15 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.24 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal USD 161,184 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD 7,000 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap DebtInstrumentUnamortizedDiscountCurrent Debt Instrument, Unamortized Discount, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD 0 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap DebtInstrumentUnamortizedPremium Debt Instrument, Unamortized Premium USD 9,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DeferredCompensationLiabilityClassifiedNoncurrent Deferred Compensation Liability, Classified, Noncurrent USD 82,000 2024-04-15 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DeferredCompensationLiabilityCurrent Deferred Compensation Liability, Current USD 388,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 0 2015-09-30 2015 Q3 10-Q 2015-11-12 0001121781-15-000315
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredRentCredit Deferred Rent Credit USD 0 2017-09-30 2017 Q3 10-Q 2017-11-20 0001121781-17-000077
us-gaap DeferredRevenue Deferred Revenue USD 189,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 269,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 17.40M 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsGrossCurrent Deferred Tax Assets, Gross, Current USD 795,000 2016-12-31 2016 FY 10-K 2017-03-22 0001654954-17-002258
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 15.61M 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration USD 3.00M 2025-12-31 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 211,000 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsOtherLossCarryforwards Deferred Tax Assets, Other Loss Carryforwards USD 48.60M 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits USD 440,000 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other USD 861,000 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 237,000 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 17.40M 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Deferred Tax Liabilities, Intangible Assets USD 0 2016-12-31 2016 FY 10-K 2017-03-22 0001654954-17-002258
us-gaap DepositAssets Deposit Assets USD 493,000 2020-09-30 2020 Q3 10-Q/A 2020-11-05 0001121781-20-000080
us-gaap DepositLiabilitiesAccruedInterest Deposit Liabilities, Accrued Interest USD 13,760 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap Deposits Deposits USD 99,000 2019-06-30 2019 Q2 10-Q 2020-02-11 0001121781-20-000011
us-gaap Depreciation Depreciation USD 7,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 483,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-25 0001121781-15-000054
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap DepreciationNonproduction Depreciation, Nonproduction USD 6.95M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap DerivativeFairValueOfDerivativeLiability Derivative Liability, Fair Value, Gross Liability USD 20,000 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD 39,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DerivativeLiabilities Derivative Liability USD 37,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DerivativeLiabilitiesCurrent Derivative Liability, Current USD 43,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap DerivativeLiabilityFairValueOfCollateral Derivative Liability, Fair Value of Collateral USD 326,016 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap DerivativeLiabilityNotionalAmount Derivative Liability, Notional Amount USD 298,884 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap DirectFinancingLeaseRevenue Direct Financing Lease, Revenue USD 4.00M 2022-06-01 2022-06-22 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment USD 647.00M 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap DividendsPayableCurrent Dividends Payable, Current USD 120,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 3,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap DividendsPreferredStockStock Dividends, Preferred Stock, Stock USD 36,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 497,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap DueToRelatedPartiesCurrentAndNoncurrent Due to Related Parties USD 354,000 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap DueToRelatedPartiesNoncurrent Due to Related Parties, Noncurrent USD 83,000 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.02 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.29 2017-01-01 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.02 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.25 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.04 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity USD 1.10M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 1.12M 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 170,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap EmployeeStockOwnershipPlanESOPDeferredShares Employee Stock Ownership Plan (ESOP), Deferred Shares USD 284,000 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap EntityWideRevenueMajorCustomerPercentage Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) pure 0.65 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-26 0001121781-14-000055
us-gaap EquityFairValueDisclosure Equity, Fair Value Disclosure USD -2.23M 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage pure 0.1 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap ExcessStockSharesIssued Excess Stock, Shares Issued shares 875,000 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap ExplorationExpense Exploration Expense USD 270,000 2025-01-01 2025-12-31 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ExtinguishmentOfDebtAmount Extinguishment of Debt, Amount USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap FinanceLeaseRightOfUseAssetAmortization Finance Lease, Right-of-Use Asset, Amortization USD 50,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 177,685 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap GainLossOnRepurchaseOfDebtInstrument Gain (Loss) on Repurchase of Debt Instrument USD 160,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap GainLossOnSaleOfDerivatives Gain (Loss) on Sale of Derivatives USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-14 0001477932-24-002788
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 8,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001477932-26-004958
us-gaap GainsLossesOnRestructuringOfDebt Gains (Losses) on Restructuring of Debt USD 60,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 1.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap GrossProfit Gross Profit USD 90,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncomeLossFromContinuingOperations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent USD -6.64M 2011-01-01 2011-12-31 2011 FY 10-K 2012-03-28 0001121781-12-000081
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -3.56M 2013-01-01 2013-06-30 2013 Q2 10-Q 2013-08-14 0001121781-13-000294
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -1.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -3.49M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap IncomeLossFromContinuingOperationsPerBasicAndDilutedShare Income (Loss) from Continuing Operations, Per Basic and Diluted Share USD/shares -0.14 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap IncomeLossFromContinuingOperationsPerBasicShare Income (Loss) from Continuing Operations, Per Basic Share USD/shares -0.01 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 164,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -164,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 0 2021-01-01 2021-03-31 2021 Q1 10-Q/A 2021-08-18 0001654954-21-009188
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -55,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 235,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -1,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 70,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap IncreaseDecreaseInCustomerDeposits Increase (Decrease) in Customer Deposits USD 32,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2020-03-09 0001121781-20-000018
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 80,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInDerivativeLiabilities Increase (Decrease) in Derivative Liabilities USD 2.20M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap IncreaseDecreaseInInsuranceSettlementsReceivable Increase (Decrease) in Insurance Settlements Receivable USD -3.62M 2011-01-01 2011-12-31 2011 FY 10-K 2012-03-28 0001121781-12-000081
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 62,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -22,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD -95,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 0 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-19 0001121781-16-000472
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -1,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD 0 2021-01-01 2021-03-31 2021 Q1 10-Q/A 2021-08-18 0001654954-21-009188
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 47.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InducedConversionOfConvertibleDebtExpense Induced Conversion of Convertible Debt Expense USD 78,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InterestAndDebtExpense Interest and Debt Expense USD 1,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001477932-24-004869
us-gaap InterestExpense Interest Expense USD 287,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001477932-26-004958
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 442,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InterestIncomeOperating Interest Income, Operating USD 0 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-14 0001477932-25-005887
us-gaap InterestIncomeOther Interest Income, Other USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 97,000 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 48,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InterestPayableCurrent Interest Payable, Current USD 488,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryFinishedGoods Inventory, Finished Goods, Gross USD 11,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryFinishedGoodsNetOfReserves Inventory, Finished Goods, Net of Reserves USD 818,000 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap InventoryLIFOReservePeriodCharge Inventory, LIFO Reserve, Period Charge USD -73,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap InventoryNet Inventory, Net USD 511,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryRawMaterials Inventory, Raw Materials, Gross USD 1.25M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryValuationReserves Inventory Valuation Reserves USD 818,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 69,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap InventoryWriteDown Inventory Write-down USD -26,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-15 0001121781-16-000420
us-gaap InvestmentIncomeDividend Investment Income, Dividend USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-05-08 0001654954-19-005469
us-gaap InvestmentIncomeInterestAndDividend Investment Income, Interest and Dividend USD 1.38 2012-07-01 2012-07-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap InvestmentInterestRate Investment Interest Rate pure 0.24 2020-05-27 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 3.62M 2011-01-01 2011-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 871,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 114,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 41,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 190,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 182,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 175,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 169,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 30,000 2025-09-30 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 197,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap Liabilities Liabilities USD 7.51M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.38M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LiabilitiesCurrent Liabilities, Current USD 6.93M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LiabilitiesFairValueDisclosureRecurring Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 6.27M 2018-03-31 2018 Q1 10-Q 2018-05-21 0001121781-18-000024
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 580,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LiabilityForFuturePolicyBenefitRemeasurementGainLoss LiabilityForFuturePolicyBenefitRemeasurementGainLoss USD 160,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LineOfCreditFacilityAverageOutstandingAmount Line of Credit Facility, Average Outstanding Amount USD 129,556 2024-07-01 2024-07-04 2025 Q2 10-Q 2025-08-14 0001477932-25-005887
us-gaap LinesOfCreditCurrent Line of Credit, Current USD 619 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap LoansInsurancePolicy Loans, Gross, Insurance Policy USD 92,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LoansPayableCurrent Loans Payable, Current USD 177,000 2014-03-31 2014 Q1 10-Q 2014-05-15 0001121781-14-000134
us-gaap LongTermDebt Long-term Debt USD 140,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 0 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 86,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 23,000 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 23,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 54,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap LongTermNotesPayable Notes Payable, Noncurrent USD 5,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap MinorityInterest Stockholders' Equity Attributable to Noncontrolling Interest USD 0 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders USD 104,000 2012-01-01 2012-12-31 2013 FY 10-K 2014-03-26 0001121781-14-000055
us-gaap NetCashProvidedByUsedInContinuingOperations Net Cash Provided by (Used in) Continuing Operations USD -277,000 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-18 0001654954-17-007742
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 1.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -1.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -1.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -2.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -60,000 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-14 0001477932-25-005887
us-gaap NotesAndLoansPayable Notes and Loans Payable USD 27,000 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap NotesAndLoansPayableCurrent Notes and Loans Payable, Current USD 0 2019-12-31 2019 Q3 10-Q 2020-03-09 0001121781-20-000018
us-gaap NotesIssued1 Notes Issued USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap NotesPayable Notes Payable USD 135,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NotesPayableCurrent Notes Payable, Current USD 130,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap NotesPayableRelatedPartiesClassifiedCurrent Notes Payable, Related Parties, Current USD 0 2023-03-31 2023 Q1 10-Q 2023-05-15 0001477932-23-003493
us-gaap NotesPayableRelatedPartiesCurrentAndNoncurrent Notes Payable, Related Parties USD 0 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap NotesPayableRelatedPartiesNoncurrent Notes Payable, Related Parties, Noncurrent USD 497,170 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap OperatingExpenses Operating Expenses USD 1.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -1.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseCost Operating Lease, Cost USD 109,404 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 126,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 674,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 99,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 575,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeasePayments Operating Lease, Payments USD 78,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 616,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 69,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 159,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 120,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 26,000 2018-09-30 2018 Q3 10-Q 2018-11-14 0001121781-18-000063
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 30,000 2019-09-30 2019 Q3 10-Q 2020-03-09 0001121781-20-000018
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 30,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 29,000 2019-09-30 2019 Q3 10-Q 2020-03-09 0001121781-20-000018
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 66.30M 2025-12-31 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 8,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherAccruedLiabilitiesCurrentAndNoncurrent Other Accrued Liabilities USD 7,000 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap OtherAssetsCurrent Other Assets, Current USD 109,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 17,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherCommitment Other Commitment USD 2,000 2024-04-15 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherCostAndExpenseOperating Other Cost and Expense, Operating USD 27,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherEmployeeRelatedLiabilitiesCurrent Other Employee-related Liabilities, Current USD 671,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherExpenses Other Expenses USD 2,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0001477932-22-003472
us-gaap OtherIncome Other Income USD 14,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001477932-26-004958
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 262,000 2015-03-31 2015 Q1 10-Q 2015-05-13 0001121781-15-000121
us-gaap OtherNoncashExpense Other Noncash Expense USD 20,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -7,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 16,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -462,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherNotesPayable Other Notes Payable USD 5,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD 4,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap OtherPreferredStockDividendsAndAdjustments Other Preferred Stock Dividends and Adjustments USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 100,000 2020-03-31 2020 Q1 10-Q 2020-07-07 0001654954-20-007405
us-gaap PaymentsForFees Payments for Other Fees USD 31,650 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap PaymentsForRent Payments for Rent USD 750,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 80,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap PaymentsOfDebtRestructuringCosts Payments of Debt Restructuring Costs USD 125,000 2022-09-03 2022-09-08 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap PaymentsOfLoanCosts Payments of Loan Costs USD 281,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap PaymentsToAcquireLoansReceivable Payments to Acquire Loans Receivable USD 4,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap PaymentsToAcquireProductiveAssets Payments to Acquire Productive Assets USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-22 0001654954-17-002258
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap PaymentsToFundLongtermLoansToRelatedParties Payments to Fund Long-term Loans to Related Parties USD 92,399 2022-06-01 2022-06-22 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap PreferredStockConvertibleSharesIssuable PreferredStockConvertibleSharesIssuable shares 45.55M 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD -2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 500,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap PreferredStockDividendsShares Preferred Stock Dividends, Shares shares 65,000 2022-08-29 2022-09-01 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap PreferredStockLiquidationPreference Preferred Stock, Liquidation Preference Per Share USD/shares 1,248 2017-06-30 2017 Q2 10-Q 2017-08-18 0001654954-17-007742
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 286,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0.3 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0.3 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 1.34M 2013-06-30 2013 Q2 10-Q 2013-08-14 0001121781-13-000294
us-gaap PremiumsPercentageAssumedToNet SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net pure 0.5 2025-01-01 2025-12-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap PrepaidExpenseAndOtherAssets Prepaid Expense and Other Assets USD 356,000 2017-06-30 2017 Q2 10-Q 2017-08-18 0001654954-17-007742
us-gaap PrepaidExpenseCurrentAndNoncurrent Prepaid Expense USD 12,000 2016-09-30 2016 Q3 10-Q 2016-12-05 0001121781-16-000585
us-gaap PrepaidInsurance Prepaid Insurance USD 133,000 2016-09-30 2016 Q3 10-Q 2016-12-05 0001121781-16-000585
us-gaap PriceRiskCashFlowHedgeLiabilityAtFairValue Price Risk Cash Flow Hedge Liability, at Fair Value USD 50,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap PrincipalAmountOutstandingOnLoansSecuritized Principal Amount Outstanding on Loans Securitized or Asset-backed Financing Arrangement USD 625,444 2022-06-30 2022 Q2 10-Q 2022-08-15 0001477932-22-006064
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001477932-26-004958
us-gaap ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan USD 3.20M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 526,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 519,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants USD 400,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 480,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 400,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0001477932-25-002200
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 126,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-14 0001121781-18-000063
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 526,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProceedsFromRelatedPartyDebt Proceeds from Related Party Debt USD 160,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ProceedsFromRepurchaseOfEquity Proceeds from (Repurchase of) Equity USD 217,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-22 0001121781-17-000030
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 56,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProceedsFromSaleOfTrustAssetsToPayExpenses Proceeds from Sale of Trust Assets to Pay Expenses USD 3.20M 2022-01-01 2022-12-31 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap ProceedsFromShortTermDebt Proceeds from Short-term Debt USD -90,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0001477932-22-003472
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 1.83M 2013-01-01 2013-06-30 2013 Q2 10-Q 2013-08-14 0001121781-13-000294
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 980,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProductWarrantyAccrual Standard and Extended Product Warranty Accrual USD 2,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -1.10M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001477932-26-004958
us-gaap ProFormaWeightedAverageSharesOutstandingDiluted Pro Forma Weighted Average Shares Outstanding, Diluted shares 27.34M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap PropertyPlantAndEquipmentDisposals Property, Plant and Equipment, Disposals USD 647,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-04-07 0001654954-21-003915
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 1.59M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ProvisionForDoubtfulAccounts Accounts Receivable, Credit Loss Expense (Reversal) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RepaymentsOfDebt Repayments of Debt USD 10,000 2024-07-01 2024-07-23 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 571,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RepaymentsOfRelatedPartyDebt Repayments of Related Party Debt USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RepurchaseAgreementsInterestExpenseAmount Repurchase Agreements, Interest Expense Amount USD 29,776 2022-06-01 2022-06-22 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 282,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RestructuringReserve Restructuring Reserve USD 972,000 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -159.39M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount USD 7,442 2023-09-30 2023 Q3 10-Q 2023-11-13 0001477932-23-008286
us-gaap Revenues Revenues USD 92,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap RevenuesFromExternalCustomers Revenue from External Customers (Deprecated 2013-01-31) USD 653,000 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-26 0001121781-14-000055
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 642,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 0.29 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 4,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-21 0001121781-18-000024
us-gaap SellingAndMarketingExpense Selling and Marketing Expense USD 68,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ServicingLiabilityAtFairValueOtherChangesInFairValue Servicing Liability at Fair Value, Other Changes in Fair Value USD -8,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 101,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage pure 0.25 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price USD/shares 0.25 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.934 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.038 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised shares 4.83M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations shares 900,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted shares 5.18M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other shares 4.83M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number shares 32.39M 2024-09-30 2024 Q3 10-Q 2024-11-14 0001477932-24-007162
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 26,616 2015-12-31 2015 FY 10-K 2016-03-15 0001121781-16-000420
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 91,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 2.65M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 0.31 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 0 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-12 0001121781-14-000322
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 657,431 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 0 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 0.26 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value USD/shares 0 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-12 0001121781-14-000322
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 24,205 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 625,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value USD/shares 0 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-12 0001121781-14-000322
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 625,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 0.14 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares shares 1 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares shares 7 2017-01-01 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value USD/shares 48,613 2017-01-01 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price USD/shares 0 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 135,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 3.45M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 0.39 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 56.83M 2015-03-31 2015 Q1 10-Q 2015-05-13 0001121781-15-000121
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 56.83M 2015-03-31 2015 Q1 10-Q 2015-05-13 0001121781-15-000121
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 117 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 0 2017-01-01 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 0 2017-01-01 2017-12-31 2017 FY 10-K/A 2018-04-20 0001654954-18-004170
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum pure 0.1 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period shares 15.32M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0.15 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0001477932-25-002200
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 0.45 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 0.21 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 0.29 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price USD/shares 0.28 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap SharePrice Share Price USD/shares 0.4 2025-06-30 2025 Q2 10-Q 2025-08-14 0001477932-25-005887
us-gaap SharesIssued Shares, Issued shares 116,364 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 0.04 2019-12-17 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap SharesOutstanding Shares, Outstanding shares 86.15M 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ShortTermBankLoansAndNotesPayable Short-term Bank Loans and Notes Payable USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap ShortTermBorrowings Short-term Debt USD 646,000 2019-12-31 2019 FY 10-K 2020-04-20 0001654954-20-004236
us-gaap ShorttermDebtFairValue Short-term Debt, Fair Value USD 431,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap ShortTermDebtInterestRateIncrease Short-term Debt, Interest Rate Increase pure 0.033 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap ShortTermNonBankLoansAndNotesPayable Short-term Non-bank Loans and Notes Payable USD 47,162 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants USD 15.94M 2012-07-01 2012-07-30 2012 Q3 10-Q 2012-11-13 0001121781-12-000323
us-gaap StockGrantedDuringPeriodValueSharebasedCompensationForfeited Shares Granted, Value, Share-based Payment Arrangement, Forfeited USD 178,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -6.14M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap StockholdersEquityBeforeTreasuryStock Stockholders' Equity before Treasury Stock USD -132,000 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD -5.20M 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap StockIssued1 Stock Issued USD 104,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001477932-24-004869
us-gaap StockIssuedDuringPeriodSharesConversionOfUnits Stock Issued During Period, Shares, Conversion of Units shares 6.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services shares 98,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-30 0001477932-23-001899
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 813,916 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap StockIssuedDuringPeriodSharesOther Stock Issued During Period, Shares, Other shares 813,916 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture shares 200,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-25 0001121781-15-000054
us-gaap StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Shares Issued, Shares, Share-based Payment Arrangement, Forfeited shares 3,262 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0001477932-22-003472
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 203,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap StockIssuedDuringPeriodValueConversionOfUnits Stock Issued During Period, Value, Conversion of Units USD 2.56M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-21 0001654954-21-006101
us-gaap StockIssuedDuringPeriodValueIssuedForCash Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) USD 162,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 592,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0001477932-22-003472
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 205,000 2025-01-01 2025-03-31 2026 Q1 10-Q 2026-05-15 0001477932-26-003195
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001477932-22-008459
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD 60,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001477932-24-004869
us-gaap StockIssuedDuringPeriodValueStockDividend Stock Issued During Period, Value, Stock Dividend USD 14,000 2021-01-01 2021-03-31 2021 Q1 10-Q/A 2021-08-18 0001654954-21-009188
us-gaap StockOptionExercisePriceIncrease Stock Option, Exercise Price, Increase USD/shares 0.65 2022-08-29 2022-09-01 2023 FY 10-K 2024-03-28 0001477932-24-001549
us-gaap StockOptionPlanExpense Stock or Unit Option Plan Expense USD 93,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 300,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 50,000 2021-06-30 2021 Q2 10-Q 2021-08-18 0001654954-21-009195
us-gaap TreasuryStockCommonValue Treasury Stock, Common, Value USD 132,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap TreasuryStockValue Treasury Stock, Value USD 132,000 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap UnamortizedDebtIssuanceExpense Unamortized Debt Issuance Expense USD 48,000 2015-12-31 2015 FY 10-K 2016-03-15 0001121781-16-000420
us-gaap UnrealizedGainLossOnDerivatives Unrealized Gain (Loss) on Derivatives USD -91,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 312,693 2021-09-30 2021 Q3 10-Q 2021-11-15 0001654954-21-012222
us-gaap UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward (Deprecated 2014-01-31) USD 61.80M 2012-12-31 2012 FY 10-K 2013-03-27 0001121781-13-000037
us-gaap WarrantExercisePriceDecrease Warrant, Exercise Price, Decrease USD/shares 0.15 2022-08-29 2022-09-02 2025 Q3 10-Q 2025-11-13 0001477932-25-008196
us-gaap WarrantExercisePriceIncrease Warrant, Exercise Price, Increase USD/shares 1.5 2021-05-01 2021-05-17 2025 FY 10-K 2026-03-31 0001477932-26-001723
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 873,000 2013-06-30 2013 Q2 10-Q 2013-08-14 0001121781-13-000294
us-gaap WarrantsNotSettleableInCashFairValueDisclosure Warrants Not Settleable in Cash, Fair Value Disclosure USD 0 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap WeightedAverageLimitedPartnershipUnitsOutstandingDiluted Weighted Average Limited Partnership Units Outstanding, Diluted shares 13.38M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0001477932-22-001704
us-gaap WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma Weighted Average Number Basic Shares Outstanding Adjustment, Pro Forma shares 68.29M 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 68.29M 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001477932-25-003835
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 94.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 946 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-22 0001121781-17-000030
us-gaap WeightedAverageNumberOfSharesIssuedBasic Weighted Average Number of Shares Issued, Basic shares 94.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 94.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001477932-26-007012

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →